Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Shares Issued (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Shares Issued for 4 consecutive years, with $1.0 million as the latest value for Q4 2025.

  • Quarterly Shares Issued changed N/A to $1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, up 455.69% year-over-year, with the annual reading at $1.2 million for FY2025, 1270.79% up from the prior year.
  • Shares Issued hit $1.0 million in Q4 2025 for Taysha Gene Therapies, up from $122000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $11.3 million in Q3 2022 to a low of -$11.4 million in Q4 2022.
  • Historically, Shares Issued has averaged -$807750.0 across 4 years, with a median of $69000.0 in 2024.
  • Biggest five-year swings in Shares Issued: plummeted 96.02% in 2023 and later skyrocketed 188.46% in 2025.
  • Year by year, Shares Issued stood at -$11.4 million in 2022, then soared by 96.21% to -$432000.0 in 2023, then surged by 114.58% to $63000.0 in 2024, then soared by 1523.81% to $1.0 million in 2025.
  • Business Quant data shows Shares Issued for TSHA at $1.0 million in Q4 2025, $122000.0 in Q3 2025, and $75000.0 in Q1 2025.